Factors Associated with Survival of HIV/HBV Co-infected Patients in Uganda
DOI:
https://doi.org/10.61538/ajer.v4i2.447Abstract
The main objective of the study was to identify factors that affect survival of HIV/HBV coinfected patients. The study used data from TASO Uganda. Patients who registered with the organization between 2005 and 2010 were followed to determine their survival. The covariates of study were age, education level, number of sex partners, Disease stage, weight, HBV related condition, being on ARV’s. To estimate the survival function for every subgroup of each variable, the product- limit method developed by Kaplan and Meier was used (Kaplan and Meier, 1958) and a log rank test to compare the survivorship functions across several groups. Lastly,a proportional hazards model was used to examine the joint effect of the covariates on the duration of survival assuming a Gompertz distribution for the time variable. The study revealed the duration of survival for HIV/HBV co-infected patients increased with increasing weight. Patients who had Hepatocellular carcinoma or Cirrhosis at diagnosis were at an increased risk of death as compared to those who had chronic active hepatitis B. Patients on ARVs had an increased death rate as compared to those who were not on ARVs, because the study showed that majority of the Patients seek for treatment when they are infected with Carcinoma, the old stage of Hepatitis B. Given the fact that ARVs have been thought to make life better for HIV/AIDS patients, there is need for further research in this area. Patients who were educated had a reduced death rate as compared to the uneducated ones. Therefore, emphasis should be on designing Information Education Communication (IEC) materials to sensitize the uneducated HIV/HBV co-infected patients on effects of non compliance and unbalanced diets.References
Aalen, O. (1978). “Nonparametric inference for a family of counting processeâ€s. Annals of Statistics, 6: 701-726.
Akaike, H. (1973). “Information theory and an extension of the maximum likelihood principleâ€. Second international symposium on information theory: 267-281
AMREF. (1999). Communicable diseases. A Manual for health workers in Sub-Saharan Africa. 3rd edition. Nairobi: AMREF.
Andre, F. (2004). Hepatitis B a comprehensive prevention, diagnosis, and treatment program – past, present, and future. Journal of Gastroenterology and Hepatology; 19:1–4.
Ansa, VO. Udoma, EJ. Umoh, MS & Anah, MU. (2002). Occupational risk of infection by human immunodeficiency and hepatitis B viruses among health workers in southeastern Nigeria. East African Medical Journal ; 79:254–256.
Benhamou, Y. Katlama, C. Lunel, F. Coutellier, A. Dohin, E. Hamm, N. Tubiana, R. Herson, S.
Poynard, T. & Opolon, P. (1996). “Effects of lamivudine on replication of hepatitis B virus in HIV-infected menâ€. Annals of Internal Medicine ; 125:705–712.
Bwogi, J. (2009). “Hepatitis B infection is highly endemic in Ugandaâ€. Findings from a national serosurvey Africa Health Science. June; 9(2): 98–108.
Carr, A. &Cooper, DA. (1997). “Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitorâ€. Lancet; 349:995–996.
Dye, C. Scheele, S. Dolin, P. Pathania, V. & Raviglione, M. C. (1999). Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. Journal of the American Medical Association, 282: 677-686.
Feld, J. Ocama, P. & Ronald, A. (2005). The liver in HIV in Africa. Infectious Disease Clinic,
Department of Medicine, Mulago Hospital, Kampala Uganda
Antiviral Therapy 10:953–965
Giovanni, B.G. Gianfranca, S. Davide, F.P. Salvatore, L. Chiaramonte, M. Stroffolini,T. Colucci, G. & Rizzetto, M. (2003). Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study; 21 August 2003.
Hoffmann, C. & Thio, C. (1990). “Clinical implications of HIV and hepatitis B co-infection in Asia and Africaâ€. The Lancet Infectious Diseases, Volume 7, Issue 6, Pages 402-409
Hogg, R. S. Heath, K. V. & Yip, B. (1998). “Improved survival among HIV-infected individuals following initiation of antiretroviral therapyâ€. JAMA, 279: 450-454.
Hudson, C.P. Hennis, A.J. Kataaha, P. Lloyd, G. Moore, AT. Sutehall, GM. Whetstone, R. Wreghitt ,T. & Karpas, A.(1988). Risk factors for the spread of AIDS in rural Africaâ€: evidence from a comparative seroepidemiological survey of AIDS, hepatitis B and syphilis in southwestern Uganda. School of Clinical Medicine, University of Cambridge. Aug;2(4):255-60.
Kaplan, E. L. & Meier, P. (1958). Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53: 457-481.
Klein, J. P. & Moeschberger, M. L. (2003). Survival Analysis: Techniques for Censored and Truncated Data. 2nd edition. New York: Springer.
Laurent, C. Henzel, D. Mulanga-Kabeya, C. Maertens, G. Larouze, B. & Delaporte, E. (2001). Seroepidemiological survey of hepatitis C virus among commercial sex workers and pregnant women in Kinshasa, Democratic Republic of Congo. International Journal of Epidemiology; 30:872–877.
Lazizi, Y. Grangeot-Keros, L. Delfraissy, JF. Boue, F. Dubreuil, P. Badur, S. & Pillot, J.(1988). Reappearance of hepatitis B virus in immune patients infected with the human immunodeficiency virus type 1. The Journal of Infectious Diseases ; 158:666–667.
Lee, T. E. (1992). Statistical Methods for Survival Data Analysis. 2nd Edition, New York: John Wiley and Sons, Inc
Menendez, C. Sanchez-Tapias, JM. Kahigwa, E. Mshinda, H. Costa, J. Vidal ,J. Acosta, C. Lopez-Labrador, X. Olmedo, E. Navia, M. Tanner, M. Rodes, J. & Alonso, PL.(1999). Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. Journal of Medical Virology ; 58:215–220.
Moore, D. Lietchy, C. Ekwaru, P. Were, W. Mwimu, G. Solberg, P. Rutherford, G. & Mermin, J. (2007). Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS, 21(6): 713-719.
Nelson, W. (1972). “Theory and applications of hazard plotting for censored failure dataâ€. Technometrics, 14: 945-965.
Nunez ,M. Perez-Olmeda ,M. Diaz, B. Rios, P. Gonzalez-Lahoz, J. & Soriano, V. (2002). Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS ; 16:2352–2354.
Sutcliffe, S. Taha, TE. Kumwenda, NI. Taylor, E. & Liomba, GN. (2002). HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi. Journal of Acquired Immune Deficiency Syndromes ; 31:90–97.
Tural, C. Fuster ,D. Tor, J. Ojanguren, I. Sirera, G. Ballesteros, A. Lasanta, JA. Planas, R. ReyJoly, C. & Clotet, B. (2003).Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. Journal of Viral Hepatitis; 10:118–125.
Thio, CL. Seaberg, E.C. Skolasky, R. Jr. Phair, J. Visscher, B. Munoz, A. Thomas, D.L.(2002). The Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet ; 360:1921–1926.
UNAIDS. (1996). The Status and Trends of the Global HIV/AIDS Pandemic. Final Report July 5-6.
USAID. (2006). Infectious diseases. www.usaid.gov. Accessed on 12/11/2010.
Vento, S. Perri, D.G. Garofano, T. Concia, E. & Bassetti, D. (1989). “Reactivation of hepatitis B in AIDSâ€. Lancet ; 2:108–109.
Wit, F.W. Weverling, G.J. Weel, J. Jurriaans, S. & Lange, J.M. (2002). Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. The Journal of Infectious Diseases. ; 186:23–31.
WHO. (2004).Global Hepatitis B control: Surveillance, Planning and Financing. Geneva:
WHO. (2006). World Health Report: Reducing Risks, Promoting Healthy Life. Geneva:
